Proficio Capital Partners LLC Invests $3.83 Million in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Proficio Capital Partners LLC purchased a new position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 31,492 shares of the biotechnology company’s stock, valued at approximately $3,829,000.

Other hedge funds have also recently made changes to their positions in the company. Manchester Capital Management LLC boosted its position in shares of Sarepta Therapeutics by 86.6% in the 4th quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 110 shares in the last quarter. MassMutual Private Wealth & Trust FSB raised its holdings in Sarepta Therapeutics by 169.6% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 156 shares during the last quarter. Sunbelt Securities Inc. raised its holdings in Sarepta Therapeutics by 446.2% in the 3rd quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company’s stock worth $35,000 after acquiring an additional 232 shares during the last quarter. Huntington National Bank raised its holdings in Sarepta Therapeutics by 150.9% in the 3rd quarter. Huntington National Bank now owns 291 shares of the biotechnology company’s stock worth $36,000 after acquiring an additional 175 shares during the last quarter. Finally, Newbridge Financial Services Group Inc. purchased a new position in Sarepta Therapeutics in the 4th quarter worth approximately $36,000. 86.68% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Sarepta Therapeutics news, Director Kathryn Jean Boor sold 1,636 shares of the stock in a transaction on Thursday, December 5th. The stock was sold at an average price of $125.55, for a total value of $205,399.80. Following the completion of the sale, the director now owns 5,880 shares in the company, valued at approximately $738,234. This represents a 21.77 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the stock in a transaction on Thursday, December 12th. The stock was sold at an average price of $124.84, for a total value of $1,310,820.00. Following the completion of the sale, the director now owns 22,840 shares of the company’s stock, valued at $2,851,345.60. The trade was a 31.49 % decrease in their position. The disclosure for this sale can be found here. 7.70% of the stock is owned by insiders.

Sarepta Therapeutics Price Performance

Shares of Sarepta Therapeutics stock opened at $102.86 on Wednesday. Sarepta Therapeutics, Inc. has a one year low of $99.50 and a one year high of $173.25. The stock’s fifty day moving average is $115.12 and its 200 day moving average is $122.01. The stock has a market cap of $9.83 billion, a P/E ratio of 82.29 and a beta of 0.75. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the stock. HC Wainwright restated a “sell” rating and issued a $75.00 price objective on shares of Sarepta Therapeutics in a report on Thursday, February 27th. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Sarepta Therapeutics in a report on Tuesday, February 11th. They issued a “hold” rating and a $136.00 price objective for the company. Piper Sandler decreased their price objective on shares of Sarepta Therapeutics from $200.00 to $182.00 and set an “overweight” rating for the company in a report on Wednesday, November 27th. Royal Bank of Canada decreased their price objective on shares of Sarepta Therapeutics from $165.00 to $161.00 and set an “outperform” rating for the company in a report on Thursday, February 27th. Finally, Evercore ISI decreased their price objective on shares of Sarepta Therapeutics from $179.00 to $170.00 and set an “outperform” rating for the company in a report on Thursday, November 7th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $173.52.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.